CN104341475A - Linezolid-adenosine type multi-target-point antibacterial compound as well as preparation method and application thereof - Google Patents

Linezolid-adenosine type multi-target-point antibacterial compound as well as preparation method and application thereof Download PDF

Info

Publication number
CN104341475A
CN104341475A CN201410534207.7A CN201410534207A CN104341475A CN 104341475 A CN104341475 A CN 104341475A CN 201410534207 A CN201410534207 A CN 201410534207A CN 104341475 A CN104341475 A CN 104341475A
Authority
CN
China
Prior art keywords
base
methyl
piperazine
methylamino
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410534207.7A
Other languages
Chinese (zh)
Inventor
肖竹平
魏伟
欧阳辉
朱娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jishou University
Original Assignee
Jishou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jishou University filed Critical Jishou University
Priority to CN201410534207.7A priority Critical patent/CN104341475A/en
Publication of CN104341475A publication Critical patent/CN104341475A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to linezolid-adenosine type compounds. The general structure formulas of the linezolid-adenosine type compounds are as shown in the specification. The linezolid-adenosine type compounds have good functions of inhibiting and killing various pathogenic bacteria; and a part of compounds have higher bacteriostatic activities in comparison with penicillin G, kalamycin, ketoconazole and linezolid in a manner of positive controls. Thus, the compounds provided by the invention can be used for preparing anti-infective medicines. The invention discloses a preparation method and biological activities of the linezolid-adenosine type compounds.

Description

Linezolid-adenosine type Mutiple Targets antimicrobial compounds and method for making thereof and purposes
Technical field
The present invention relates to the method for making of a class Linezolid-adenosine type Mutiple Targets antimicrobial compounds and their application in preparation antibacterials.
Technical background
Since the forties in 20th century penicillin be applied to clinical since, the life of countless people saved by microbiotic, therefore penicillin also become one of greatest discovery of 20th century mankind, and started new era of microbiotic research, emerge in large numbers polytype microbiotic such as cynnematin, fluoroquinolone, macrolide, aminoglycoside.But widely use due to antibiotic and abuse, the resistance problems of bacterium becomes increasingly conspicuous, research shows that bacterial drug resistance all constitutes threat to the nearly all antibacterials used clinically, if late 1980s is to the nineties, the extended spectrumβ-lactamase (ESBLs) that gram negative bacillus produces as Klebsiella Pneumoniae and escherichia coli, hydrolyzable comprises oxyimino group microbiotic (ceftazime, cefotaxime, aztreonam etc.) in interior most of beta-lactam antibacterials, thus the resistance obtained beta-lactam antibacterials.The bacterial strain more seriously producing ESBLs is often multidrug resistant strain, also has resistance to other microbiotic many.The appearance of Multidrug resistant bacteria, the particularly streptococcus aureus (MRSA) of methicillin resistance, the faecalis (VRE) of drug resistance of vancomycin, the Gram-negative bacteria (MDR-GNB) etc. of multidrug resistance, human health is made to be encountered by huge threat, have data to show, the mortality ratio that MRSA causes is more taller than HIV.It is the powerful measure alleviating this crisis that novel antibacterial medicine is applied clinically; but; the research and development of current antibacterials are in atrophy situation; 18 big drug firms are had the nineties in 20th century to be devoted to the research and development of antibacterials; be only surplus 4 to 2010 and also adhere to (AstraZeneca; Novartis, GSK and Sanofi-Aventis), regrettably AstraZeneca wherein also renunciated the research and development project of antibacterials in 2013.The contradiction of the demand and supply of novel antibacterial medicine is becoming increasingly acute because resistant organism spreads; to the great and instant global problem that antimicrobial agent has become on clinical medicine; if do not adopted an effective measure, we will be absorbed in the crisis returning to " before microbiotic epoch ".
Target spot sudden change is the main path of bacterium to certain drug resistant, and the probability of single target spot sudden change is 10 -7-10 -9between, this discovery shows, if a certain medicine can act on multiple target spot, so bacterium needs to undergo mutation at these target spots simultaneously, the approach just likely suddenlyd change by target spot is to this drug resistant, but the probability of several target spot simultaneous mutation is almost nil, therefore Mutiple Targets medicine is to the strong weapon of antimicrobial agent.Based on this thinking, the present invention is on the basis analysed in depth target structures, consider the complementary relationship of ligand molecular and target structures, the method of computer aided drug design, design and synthesize out the Linezolid that simultaneously can act on tyrosyl t-RNA synthetic enzyme (TyrRS) and rrna 50S subunit-adenosine type Mutiple Targets antimicrobial compounds, block process---the synthesis of protein of most critical bacterium vital movement from two different approach respectively, thus sensitive organism and resistant organism are produced suppress efficiently and killing action.To there is no with TyrRS and rrna 50S subunit be at present target spot, and two target spot antimicrobial compoundss occur.Experiment shows, not only antimicrobial agent is remarkably productive but also security good for the antimicrobial compounds of these novel structures.
Summary of the invention
Technical scheme of the present invention is as follows:
One class Linezolid-adenosine type Mutiple Targets antimicrobial compounds, they have following general structure:
In formula I:
R 1=Me, Et, OMe, OEt, NH 2, NHMe, H, F, Cl, Br, NO 2, CN, CO 2h or OH, me, Et, OMe, OEt, NH 2, NHMe, H, F, Cl, Br or OH, R 3=H, F, Cl, Br or OH, R 4=H, Me or Et.
Prepare a method for above-mentioned Linezolid-adenosine type Mutiple Targets antimicrobial compounds, it comprises the following steps:
Step 1: (R)-5-phthalimide methyl-2-oxazolidone (III) and salt of wormwood are joined in toluene, every g III toluene 5-18mL, after dissolving, room temperature reaction 0.5-6h, and then add 2-R 1-3-R 2the fluoro-4-of-5-(4 '-tert-butoxycarbonyl-piperazine base) bromobenzene (II) and cuprous chloride, the ratio of amount of substance: II:III: salt of wormwood: cuprous chloride=1:1:(2-7): (0.1-0.9), when solution is muddy gradually, add the benzyltriethylammoinium chloride of the 5%-10% of compound III consumption, be warming up to back flow reaction 15-24h, react complete, boil off toluene, add water, dichloromethane extraction, organic phase saturated sodium bicarbonate, saturated sodium-chloride wash, anhydrous MgSO 4drying, concentrated, silica gel column chromatography, eluent is sherwood oil-AcOEt, and the volume ratio of sherwood oil and AcOEt is 20:1-8:1, obtains (R)-(N-(2 '-R 1-3 '-R 2-5 '-fluoro-4 '-(4 "-tert-butoxycarbonyl-piperazine base)) phenyl-2-oxo-5-oxazolidinyl) methyl phthalimide (IV);
Step 2: by (R)-(N-(2 '-R 1-3 '-R 2-5 '-fluoro-4 '-(4 "-tert-butoxycarbonyl-piperazine base)) phenyl-2-oxo-5-oxazolidinyl) methyl phthalimide (IV) joins in methyl alcohol, every g IV methyl alcohol 7-30mL, after dissolving, add the hydrazine hydrate that massfraction is 80%, ratio of amount of substance: IV: anhydrous hydrazine=1:(5-8), be warming up to 50 DEG C, react 3-15h under nitrogen protection, react complete, concentrated, enriched material is water-soluble, with dichloromethane extraction, saturated sodium-chloride washs, anhydrous MgSO 4dry, concentrated, enriched material is dissolved with toluene, add diacetyl oxide, after dropwising, room temperature reaction 2-10h, react complete, suction filtration, filter residue methanol wash, obtains (R)-N-tertiary fourth oxygen formyl radical-4-(4-(5-(ethanamide methyl)-2-Yang Dai oxazolidine-3-base)-2-R 2-3-R 1-6-fluorophenyl) piperazine (V), compound (V) is dissolved in methylene dichloride, every g V methylene dichloride 6-20mL, after to be dissolved, add 80% trifluoroacetic acid aqueous solution, the ratio of amount of substance: V: trifluoroacetic acid=1:(2-7), room temperature reaction 4-14h, after reaction terminates, under ice bath with in saturated sodium bicarbonate solution and, dichloromethane extraction 3 times, concentrated, silica gel column chromatography, eluent is sherwood oil-AcOEt, the volume ratio of sherwood oil and AcOEt is 15:1-3:1, obtain (R)-4-(4-(5-(ethanamide methyl)-2-Yang Dai oxazolidine-3-base)-2-R 2-3-R 1-6-fluorophenyl) piperazine (VI),
Step 3: by 2-R 4-8-R 3-2 ', 3 '-isopropylidene adenosine (VII) and phthalic imidine are dissolved in THF, and every g VII THF 6-15mL, instills diisopropyl azodiformate (DIAD), the ratio of amount of substance: VII:PPh after dissolving 3: phthalic imidine: DIAD=1:(1.5-3): (1.5-5): (2-8), dropwise and react 7-24h under room temperature, react complete, concentrated, with the dissolve with ethanol of the anhydrous hydrazine containing 5%-10%, the ratio of amount of substance: VII: anhydrous hydrazine=1:(3-8), backflow 30min, is cooled to room temperature, filters, use ethanol rinse filter residue, filtrate concentrates, silica gel column chromatography, and eluent is sherwood oil-AcOEt, the volume ratio of sherwood oil and AcOEt is 15:1-2:1, obtains white solid 2-R 4-8-R 3-5 '-aminomethyl-2 ', 3 '-isopropylidene adenosine (VIII);
Step 4: by 2-R 4-8-R 3-5 '-aminomethyl-2 ', 3 '-isopropylidene adenosine (VIII) joins in DMF, every g VIII DMF 8-18mL, adds triethylamine and ethyl bromoacetate, the ratio of amount of substance: VIII: triethylamine: ethyl bromoacetate=1:(5-8 after dissolving): (2-3), react 8-22h under nitrogen protection, react complete, add the distilled water of 3 times of DMF volumes, extract 3 times with AcOEt, saturated common salt water washing, anhydrous MgSO 4drying, concentrated, obtain-2-(((3aR, 4R, 6R, 6aR)-6-(6-amino-2-R 4-8-R 3-9H-purine-9-base)-2, 2-dimethyl-tetrahydrofuran [3, 4-d] [1, 3] dioxolane-4-base) methylamino-) ethyl acetate (IX), compound (IX) is dissolved in THF, every g IX THF 8-15mL, after to be dissolved, add 10% aqueous sodium hydroxide solution, the ratio of amount of substance: IX: sodium hydroxide=1:(1.5-3), room temperature reaction 5-26h, after reaction terminates, add dilute hydrochloric acid neutralization, 3 times are extracted with AcOEt, concentrated, silica gel column chromatography, eluent is the sherwood oil-AcOEt of 1% acetic acid, the volume ratio of sherwood oil and AcOEt is 8:1-1:2, obtain 2-(((3aR, 4R, 6R, 6aR)-6-(6-amino-2-R 4-8-R 3-9H-purine-9-base)-2,2-dimethyl-tetrahydrofurans [3,4-d] [1,3] dioxolane-4-base) methylamino-) acetic acid (X),
Step 5: by 2-(((3aR, 4R, 6R, 6aR)-6-(6-amino-2-R 4-8-R 3-9H-purine-9-base)-2,2-dimethyl-tetrahydrofuran [3,4-d] [1,3] dioxolane-4-base) methylamino-) acetic acid (X) and (R)-4-(4-(5-(ethanamide methyl)-2-Yang Dai oxazolidine-3-base)-2-R 2-3-R 1-6-fluorophenyl) piperazine (VI) adds in methylene dichloride, every g X methylene dichloride 5-20mL, TBTU and triethylamine is added after to be dissolved, the ratio of amount of substance is: X:IV:TBTU: triethylamine=1:(1.2-2): (1.5-3): (2-8), room temperature backflow 5-17h, after completion of the reaction, concentrated, column chromatography, eluent is the chloroform-methanol containing 0.1% acetic acid, and the volume ratio of chloroform and methyl alcohol is 80:1-40:1, obtain N-(((S)-3-(4-(4-(2-(((3aR, 4R, 6R, 6aR)-6-(6-amino-2-R 4-8-R 3-9H-purine-9-base)-2,2-dimethyl-tetrahydrofurans [3,4-d] [1,3] dioxolane-4-base) methylamino-) ethanoyl) piperazine-1-base)-2-R 1-3-R 2the fluoro-phenyl of-5-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (XI);
Step 6: by N-(((S)-3-(4-(4-(2-(((3aR, 4R, 6R, 6aR)-6-(6-amino-2-R 4-8-R 3-9H-purine-9-base)-2,2-dimethyl-tetrahydrofurans [3,4-d] [1,3] dioxolane-4-base) methylamino-) ethanoyl) piperazine-1-base)-2-R 1-3-R 2the fluoro-phenyl of-5-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (XI) is dissolved in methylene dichloride, every g XII methylene dichloride 8-30mL, after to be dissolved, add 80% trifluoroacetic acid, the ratio of amount of substance: XII: trifluoroacetic acid=1:(1.5-3), room temperature reaction 7-18h, after, with saturated sodium bicarbonate solution neutralization, extraction into ethyl acetate 3 times, saturated common salt water washing, anhydrous MgSO 4drying, concentrated, silica gel column chromatography, eluent is chloroform-methanol, and the volume ratio of chloroform and methyl alcohol is 60:1-20:1, obtains Linezolid-adenosine type compound (I), wherein said R 1, R 2, R 3and R 4definition identical with above-mentioned definition.
Linezolid of the present invention-adenosine type Mutiple Targets antimicrobial compounds, to multiple germ, comprises resistant organism, and have and suppress preferably and killing action, wherein some is than positive control penicillin G, kalamycin, and KETOKONAZOL and Linezolid have more high bacteriostatic activity.Therefore may be used for preparing anti-infectives.
Embodiment
Further describe the present invention by following examples, but scope of the present invention should be noted not by any restriction of these embodiments.
Embodiment 1:N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-3-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) preparation of ethanamide (58)
Step 1: 12.31g (0.05mol) (R)-5-phthalimide methyl-2-oxazolidone and 16g (0.116mol) salt of wormwood are joined in 90mL toluene, after dissolving, room temperature reaction 2h, and then add 17.96g (0.05mol) tertiary butyl 4-(the bromo-2-fluorophenyl of 4-) piperazine-1-carboxylate salt and 0.98g (0.01mol) cuprous chloride, solution become light yellow and muddy gradually time, add 1.0g benzyltriethylammoinium chloride, be warming up to 120 DEG C of back flow reaction 24h, react complete, boil off toluene, add 60mL water, separate out solid, suction filtration, filtrate divides 3 extractions with 300mL methylene dichloride, organic phase saturated sodium bicarbonate, saturated sodium-chloride washs, anhydrous MgSO 4dry, concentrated, silica gel (200-300 order) column chromatography purification, the volume ratio of eluent is: sherwood oil: AcOEt=13:1,17.52g white solid (R)-(N-(3 '-fluoro-4 '-(4 "-tert-butoxycarbonyl-piperazine base)) phenyl-2-oxo-5-oxazolidinyl) methyl phthalimide, productive rate: 67%, fusing point: 181-183 DEG C.
Step 2: 26.23g (0.05mol) (R)-(N-(3 '-fluoro-4 '-(4 "-tert-butoxycarbonyl-piperazine base)) phenyl-2-oxo-5-oxazolidinyl) methyl phthalimide is dissolved in 200mL methyl alcohol, after to be dissolved, add the hydrazine hydrate that 10mL massfraction is 80%, be warming up to 50 DEG C, react 8h under nitrogen protection, react complete, concentrated, enriched material is soluble in water, with 900mL dichloromethane extraction 3 times, organic phase 100mL saturated sodium-chloride washing, anhydrous MgSO 4dry, concentrated, enriched material is dissolved with 200mL toluene, add 10mL diacetyl oxide, after dropwising, room temperature reaction 2h, react complete, suction filtration, filter residue methanol wash, obtain 19.47g (R)-tertiary butyl 4-(4-(5-(acetamidomethyl)-2-Yang Dai oxazolidine-3-base)-2-fluorophenyl) piperazine-1-carboxylate salt, (R)-tertiary butyl 4-(4-(5-(acetamidomethyl)-2-Yang Dai oxazolidine-3-base)-2-fluorophenyl) piperazine-1-carboxylate salt is dissolved in 140mL methylene dichloride, after to be dissolved, add 12mL80% trifluoroacetic acid aqueous solution, room temperature reaction 12h, after reaction terminates, to add under ice bath in saturated sodium bicarbonate solution and, 600mL dichloromethane extraction 3 times, concentrated, silica gel (200-300 order) column chromatography purification, the volume ratio of eluent is: sherwood oil: AcOEt=7:1, obtain 11.77g white solid (R)-N-((3-(the fluoro-4-of 3-(piperazine-1-base) phenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide, productive rate: 70%, fusing point: 204-206 DEG C.
Step 3: by 15.37g (0.05mol) 2 ', 3 '-isopropylidene adenosine, 19.67g (0.075mol) PPh 3join in the anhydrous THF of 100mL with 11.03g (0.075mol) phthalic imidine, 19.8mL (0.1mol) diisopropyl azodiformate (DIAD) is instilled after dissolving, dropwise and react 4h under room temperature, react complete, concentrated, the dissolve with ethanol of the anhydrous hydrazine of 6% is contained with 4mL, backflow 30min, be cooled to room temperature, filter, use ethanol rinse filter residue, filtrate concentrates, silica gel (200-300 order) column chromatography purification, the volume ratio of eluent is: sherwood oil: AcOEt=3:1, obtain 10.82g white solid 5 '-aminomethyl-2 ', 3 '-isopropylidene adenosine, productive rate: 71%, fusing point: 177-179 DEG C.
Step 4: by 15.31g (0.05mol) 5 '-aminomethyl-2 ', 3 '-isopropylidene adenosine joins in 130mL DMF, 38mL triethylamine and 16mL ethyl bromoacetate is added after dissolving, react 11h under nitrogen protection, react complete, add 400mL distilled water, extract 3 times with 1200mL AcOEt, saturated common salt water washing, anhydrous MgSO 4dry, concentrated, obtain 16.55g 2-(((3aR, 4R, 6R, 6aR)-6-(9H-purine-9-base)-2, 2-dimethyl-tetrahydrofuran [3, 4-d] [1, 3] dioxolane-4-base) methylamino-) ethyl acetate, by 16.55g 2-(((3aR, 4R, 6R, 6aR)-6-(9H-purine-9-base)-2, 2-dimethyl-tetrahydrofuran [3, 4-d] [1, 3] dioxolane-4-base) methylamino-) ethyl acetate is dissolved in 160mL tetrahydrofuran (THF), after to be dissolved, add 15mL 10% aqueous sodium hydroxide solution, room temperature reaction 9h, after reaction terminates, add dilute hydrochloric acid neutralization, 900mL extraction into ethyl acetate 3 times, concentrated, silica gel (200-300 order) column chromatography purification, eluent is the sherwood oil-AcOEt of 1% acetic acid, the volume ratio of sherwood oil and AcOEt is 6:1, obtain 14.27g faint yellow solid 2-(((3aR, 4R, 6R, 6aR)-6-(9H-purine-9-base)-2, 2-dimethyl-tetrahydrofuran [3, 4-d] [1, 3] dioxolane-4-base) methylamino-) acetic acid, productive rate: 78%, fusing point: 154-156 DEG C.
Step 5: by 18.22g (0.05mol) 2-(((3aR, 4R, 6R, 6aR)-6-(9H-purine-9-base)-2, 2-dimethyl-tetrahydrofuran [3, 4-d] [1, 3] dioxolane-4-base) methylamino-) acetic acid, 20.18g (0.06mol) (R)-N-((3-(the fluoro-4-of 3-(piperazine-1-base) phenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide joins in 120mL methylene dichloride, 24.08g (0.075mol) TBTU and 20mL triethylamine is added after to be dissolved, room temperature backflow 8h, after completion of the reaction, concentrated, silica gel (200-300 order) column chromatography purification, eluent is the chloroform-methanol containing 0.1% triethylamine, the volume ratio of chloroform and methyl alcohol is 52:1, obtain 26.57g2-(4-(4-((S)-5-(acetamidomethyl)-2-Yang Dai oxazolidine-3-base)-2-fluorophenyl) piperazine-1-base)-N-(((3aR, 4R, 6R, 6aR)-6-(6-amino-9H-purine-9-base)-2, 2-dimethyl-tetrahydrofuran [3, 4-d] [1, 3] dioxolane-4-base) methyl) ethanamide, productive rate: 78%, fusing point: 194-196 DEG C.
Step 6: by 34.14g (0.05mol) 2-(4-(4-((S)-5-(acetamidomethyl)-2-Yang Dai oxazolidine-3-base)-2-fluorophenyl) piperazine-1-base)-N-(((3aR, 4R, 6R, 6aR)-6-(6-amino-9H-purine-9-base)-2, 2-dimethyl-tetrahydrofuran [3, 4-d] [1, 3] dioxolane-4-base) methyl) ethanamide is dissolved in 300mL methylene dichloride, after to be dissolved, add 20mL 80% trifluoroacetic acid aqueous solution, room temperature reaction 13h, after, add saturated sodium bicarbonate solution neutralization, concentrated, 900mL extraction into ethyl acetate 3 times, saturated common salt water washing, anhydrous MgSO 4dry, concentrated, silica gel (200-300 order) column chromatography purification, eluent is chloroform-methanol, the volume ratio of chloroform and methyl alcohol is 37:1, obtain 26.41g white solid N-(((S)-3-(4-(4-(2-(((2R, 3S, 4R, 5R)-5-(6-amino-9H-purine-9-base)-3, 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-3-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (58), productive rate: 82%, fusing point: 260-262 DEG C.
By the method that embodiment 1 is similar, be raw material with the Linezolid of different replacement forms and the isopropylidene adenosine of different replacement forms, synthesized the Linezolid-adenosine type Mutiple Targets antimicrobial compounds 1 ~ 85 listed by table 1.
Linezolid in table 1 general formula I-each R group of adenosine type Mutiple Targets antimicrobial compounds
Note: initial feed is all purchased from aldrich company
The extraction of embodiment 2:TyrRS and compound are to the mensuration of TyrRS activity
By the TyrRS of streptococcus aureus at e. coli expression, carry out purifying with sephadex chromatography.The activity of TyrRS is measured by aminoacylation.Enzyme reaction mixture has following component to form: 100mM TrisHCl pH 7.9,50mM KCl, 16mM MgCl 2, 5mM ATP, 3mM dithiothreitol (DTT), 4mg/mL intestinal bacteria MRE600tRNA and 10 μM of [3H] tyrosine (activity is 1.48-2.22TBq/mmol).By the tested material of TyrRS (0.2nM) and different concns at room temperature mixed culture 10 minutes, what then add equivalent is heated to 37 DEG C of above-mentioned enzyme reaction mixtures in advance, after Dual culture 5min, add isopyknic 7% ice solution of trichloroacetic acid termination reaction, filter with 96 hole Mi Libo filter membrane plates, filtrate is detected with scintillometer, and each sample repeats 4 times.Not add inhibitor in contrast.The IC of compound 50when referring to that enzymic activity lowers 50%, the concentration of test-compound, the results are shown in Table 2.
Embodiment 3: compound is to the mensuration of rrna 50S subunit transcriptional repression activity
Adopting method of transcribing separately to measure target compound and suppress rrna 50S subunit transcriptional activity, take Linezolid as positive control.Purified S.aureus70S type rrna is suspended in TMK damping fluid (10mM Tris-HCl, PH7.4,6mM MgCl, 60mM KCl, 1mM dithiothreitol (DTT)) in, add the test compound of different concns, Promega aminoacid mixture (making ultimate density reach 0.1mM), 3 μ L Promega S30 pre-compositions, and the Photinus pyralis LUC of the in-vitro transcription mRNA coding of (ultimate density reaches) 200-800nM, the final volume of responsive transcription is 10 μ L.Fluorescent value is read, IC by the multi-functional microplate reader of Victor2V 50by MDL Assay Explorer computed in software.Each test compound carries out twice independent experiment, averages, and the results are shown in Table 2.
Embodiment 4: the anti-microbial activity of compound
By bacterial suspension in MH substratum, dispersion concentration is approximately 10 5cfu ﹒ mL -1bacterium liquid is added to (every hole adds bacterium liquid 100 μ L) on 96 orifice plates, take substratum as blank, replace tested material as negative control using DMSO, gram positive bacterium take penicillin G as positive control, gram negative bacterium take kantlex as positive control, and fungi take KETOKONAZOL as positive control.Tested material is dissolved in DMSO and is made into 800,400,200,100,50,25 μ g ﹒ mL respectively -1solution is (for MIC 50be less than 5 μ g ﹒ mL -1, when carrying out a step experiment, the concentration gradient of preparation is 50,25,12.5,6.25,3.1,1.5 μ g ﹒ mL -1), join on 96 orifice plates with the amount of every hole 11 μ L that [ultimate density of liquid is respectively 80,40,20,10,5,2.5 μ gmL -1(be 5,2.5,1.25,0.63,0.31 and 0.15 μ gmL for the latter -1)], each concentration gradient does four parallel laboratory tests.The 24h cultivation 48h of 28 DEG C (fungi) cultivated by the incubator 96 orifice plates being put into 37 DEG C, then every hole adds the PBS of the every mL of 25 μ L containing 4mg MTT, under similarity condition, cultivate 4h again, every hole adds 100 μ LSDS lysates (95mL tri-distilled water+10gSDS+5mL Virahol+0.1mL concentrated hydrochloric acid) and cultivates 12h afterwards.Under 570nm, measure OD value by microplate reader, percent inhibition is calculated as follows:
Active height is with half inhibiting rate MIC 50represent, MIC 50less, the activity of this compound is higher, the results are shown in Table 2
The TyrRS of table 2 oxazolidone-adenosine type compound and rrna 50S subunit transcriptional repression activity (IC 50) and anti-microbial effect (MIC 50)
Result shows, compound 3,7,15,19,33,58,69,71,83 all has significant restraining effect to tested bacterium.7,19,33,58,69,85 pairs of staphylococcus epidermidiss show excellent anti-microbial activity, and 3,7,9,15,33,46,58,69 pairs of Klebsiella Pneumoniaes show excellent anti-microbial activity, and their anti-microbial activity has exceeded kalamycin; 7,15,36,58,69,71 pairs of Cryptococcus neoformans show excellent anti-microbial activity, and anti-mycotic activity has exceeded positive control KETOKONAZOL; 7,15,58,69,71,79 pairs of methicillin-resistant staphylococcus aureus show excellent anti-microbial activity; Compound 3,7,9,15,19,33,36,46,58,69,71,83,85 not only has good anti-microbial activity but also all serves effective restraining effect to rrna 50S subunit and TyrRS, proves Mutiple Targets antimicrobial compounds.
The above embodiment of the present invention shows: in the Linezolid-adenosine type series compound of synthesis, and the anti-microbial activity of a part is higher than positive control penicillin G, kalamycin, KETOKONAZOL or Linezolid.The anxious poison experiment of rat is shown, when the dosage of compound 7,15,33,58,69,71 reaches 5g/kg (this dosage is the non-toxic of States Pharmacopoeia specifications), do not find that rat has signs of toxicity, therefore under normal dose, they are safe as medicinal application.The fusing point of compound 1 ~ 85, mass spectrum, infrared and hydrogen modal data
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-5-fluoro-2-methyldiphenyl base-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (1):
Mp 221-223℃；EIMS m/z:557[M +]；IR(KBr)cm ﹣1:1683(C＝O)，3557(NH)； 1H NMR(DMSO-d 6)δppm：8.51(s，1H)，8.32(s，1H)，8.01(t，1H)，7.40-7.55(m，6H)，6.97(s，2H)，6.13(d，1H)，5.23(m，1H)，4.72(m，1H)，4.53(m，1H)，4.04(m，1H)，3.01-3.63(m，16H)，2.54-2.85(m，2H)，2.32(s，3H)，2.1(m，1H)，1.85(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-ethyl diphenyl of-5--3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (2):
Mp 237-239℃；EIMS m/z:521[M +]；IR(KBr)cm ﹣1:1680(C＝O)，3561(NH)； 1H NMR(DMSO-d 6)δppm：8.58(s，1H)，8.35(s，1H)，8.03(t，1H)，7.41-7.52(m，6H)，6.99(s，2H)，6.16(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.81(m，4H)，2.0(m，1H)，1.84(s，3H)，1.25(t，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-fluoro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-5-fluoro-2-methoxyl group phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (3):
Mp 275-277℃；EIMS m/z:592[M +]；IR(KBr)cm ﹣1:1682(C＝O)，3559(NH)； 1H NMR(DMSO-d 6)δppm：8.11(s，1H)，8.02(t，1H)，7.41-7.50(m，6H)，6.96(s，2H)，6.12(d，1H)，5.28(m，1H)，4.78(m，1H)，4.53(m，1H)，4.01(m，1H)，3.08-3.60(m，19H)，2.54-2.81(m，2H)，2.2(m，1H)，1.87(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-chloro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-5-fluoro-2-methoxyl group phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (4):
Mp 213-215℃；EIMS m/z:520[M +]；IR(KBr)cm ﹣1:1678(C＝O)，3564(NH)； 1H NMR(DMSO-d 6)δppm：8.10(s，1H)，8.09(t，1H)，7.47-7.52(m，6H)，6.93(s，2H)，6.11(d，1H)，5.27(m，1H)，4.70(m，1H)，4.58(m，1H)，4.04(m，1H)，3.08-3.66(m，19H)，2.50-2.81(m，2H)，2.7(m，1H)，1.85(s，3H)。
N-(((S)-3-(2-amino-6-(4-(2-(((2R; 3S; 4R; 5R)-5-(the bromo-9H-purine of 6-amino-8--9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-5-fluorine phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (5):
Mp 246-247℃；EIMS m/z:532[M +]；IR(KBr)cm ﹣1:1677(C＝O)，3562(NH)； 1H NMR(DMSO-d 6)δppm：8.12(s，1H)，8.06(t，1H)，7.28-7.53(m，6H)，6.95(s，2H)，6.21(s，2H)，6.13(d，1H)，5.29(m，1H)，4.72(m，1H)，4.56(m，1H)，4.03(m，1H)，3.08-3.64(m，16H)，2.56-2.86(m，2H)，2.4(m，1H)，1.81(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-of-5-(methylamino-) phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (6):
Mp 256-257℃；EIMS m/z:586[M +]；IR(KBr)cm ﹣1:1679(C＝O)，3565(NH)； 1H NMR(DMSO-d 6)δppm：8.15(s，1H)，8.07(t，1H)，7.84(s，1H)，7.28-7.56(m，6H)，6.91(s，2H)，6.15(d，1H)，5.28(m，1H)，4.72(m，1H)，4.59(m，1H)，4.0-4.07(m，2H)，3.01-3.69(m，19H)，2.54-2.83(m，2H)，2.6(m，1H)，1.81(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(the fluoro-2-methyl of 6-amino-8--9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-5-fluorine phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (7):
Mp 251-253℃；EIMS m/z:566[M +]；IR(KBr)cm ﹣1:1677(C＝O)，3558(NH)； 1H NMR(DMSO-d 6)δppm：8.02(t，1H)，7.66(m，1H)，7.41-7.53(m，4H)，6.99-7.08(m，4H)，6.16(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.0-4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.81(m，2H)，2.44(s，3H)，2.0(m，1H)，1.84(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-chloro-2-methyl-9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-2; 4', 5-trifluoro phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (8):
Mp 262-264℃；EIMS m/z:612[M +]；IR(KBr)cm ﹣1:1676(C＝O)，3559(NH)； 1H NMR(DMSO-d 6)δppm：8.01(t，1H)，7.30-7.54(m，5H)，6.91(s，2H)，6.14(d，1H)，5.27(m，1H)，4.79(m，1H)，4.54(m，1H)，4.0-4.04(m，1H)，3.08-3.67(m，16H)，2.51-2.84(m，2H)，2.47(s，3H)，2.6(m，1H)，1.86(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(the fluoro-9H-purine of 6-amino-2-ethyl-8--9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-2-chloro-4', 5-difluorodiphenyl base-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (9):
Mp 259-261℃；EIMS m/z:586[M +]；IR(KBr)cm ﹣1:1678(C＝O)，3559(NH)； 1H NMR(DMSO-d 6)δppm：8.09(t，1H)，7.33-7.51(m，5H)，6.95(s，2H)，6.14(d，1H)，5.25(m，1H)，4.72(m，1H)，4.57(m，1H)，4.01-4.09(m，1H)，3.08-3.67(m，16H)，2.54-2.81(m，4H)，2.5(m，1H)，1.88(s，3H)，1.29(t，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(the bromo-2-methyl of 6-amino-8--9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-2-bromo-4', 5-difluorodiphenyl base-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (10):
Mp 251-253℃；EIMS m/z:555[M +]；IR(KBr)cm ﹣1:1679(C＝O)，3569(NH)； 1H NMR(DMSO-d 6)δppm：8.05(t，1H)，7.36-7.52(m，5H)，6.93(s，2H)，6.13(d，1H)，5.26(m，1H)，4.72(m，1H)，4.56(m，1H)，4.01-4.05(m，1H)，3.06-3.61(m，16H)，2.55-2.83(m，2H)，2.41(s，3H)，2.1(m，1H)，1.86(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-4', 5-bis-fluoro-2-nitro phenylbenzene-3-base)-2-oxygen is for oxazolidine-5-base) methyl) ethanamide (11):
Mp 264-266℃；EIMS m/z:626[M +]；IR(KBr)cm ﹣1:1685(C＝O)，3574(NH)； 1H NMR(DMSO-d 6)δppm：8.58(s，1H)，8.35(s，1H)，8.03(t，1H)，7.79(m，1H)，7.30-7.39(m，4H)，6.92(s，2H)，6.11(d，1H)，5.21(m，1H)，4.71(m，1H)，4.54(m，1H)，4.0-4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.85(m，2H)，2.7(m，1H)，1.81(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-2-cyano group-4', 5-difluorodiphenyl base-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (12):
Mp 254-256℃；EIMS m/z:554[M +]；IR(KBr)cm ﹣1:1686(C＝O)，3576(NH)； 1H NMR(DMSO-d 6)δppm：8.51(s，1H)，8.32(s，1H)，8.06(t，1H)，7.74(m，1H)，7.31-7.33(m，4H)，6.94(s，2H)，6.17(d，1H)，5.26(m，1H)，4.77(m，1H)，4.58(m，1H)，4.0-4.09(m，1H)，3.04-3.66(m，16H)，2.51-2.86(m，2H)，2.3(m，1H)，1.87(s，3H)。
3-((S)-5-(acetamidomethyl)-2-Yang Dai oxazolidine-3-base)-6-(4-(2-(((2R; 3S; 4R; 5R)-5-(the bromo-2-ethyl of 6-amino-8--9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-4', 5-difluorodiphenyl base-2-carboxylic acid (13):
Mp 255-257℃；EIMS m/z:566[M +]；IR(KBr)cm ﹣1:1682(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：11(m，1H)，8.01(t，1H)，7.75(m，1H)，7.30-7.33(m，4H)，6.91(s，2H)，6.13(d，1H)，5.29(m，1H)，4.77(m，1H)，4.52(m，1H)，4.0-4.05(m，1H)，3.03-3.69(m，16H)，2.53-2.89(m，4H)，2.4(m，1H)，1.88(s，3H)，1.25(t，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-2-ethyl-8-hydroxyl-9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-hydroxy diphenyl of-4', 5-bis--3-base)-2-oxygen is for oxazolidine-5-base) methyl) ethanamide (14):
Mp 266-268℃；EIMS m/z:620[M +]；IR(KBr)cm ﹣1:1681(C＝O)，3582(NH)； 1H NMR(DMSO-d 6)δppm：8.06(t，1H)，7.84(s，1H)，7.34-7.39(m，5H)，6.97(s，2H)，6.12(d，1H)，5.38(s，1H)，5.24(m，1H)，4.75(m，1H)，4.51(m，1H)，4.0-4.09(m，1H)，3.08-3.62(m，16H)，2.56-2.85(m，4H)，2.1(m，1H)，1.84(s，3H)，1.28(t，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-chloro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the chloro-5-of-4'-fluoro-2-methyldiphenyl base-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (15):
Mp 261-263℃；EIMS m/z:600[M +]；IR(KBr)cm ﹣1:1683(C＝O)，3581(NH)； 1H NMR(DMSO-d 6)δppm：8.13(s，1H)，8.05(t，1H)，7.77(m，2H)，7.52(m，2H)，7.44(m，1H)，6.96(s，2H)，6.12(d，1H)，5.28(m，1H)，4.79(m，1H)，4.52(m，1H)，4.0-4.04(m，1H)，3.04-3.68(m，16H)，2.51-2.87(m，2H)，2.35(s，3H)，2.3(m，1H)，1.82(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-bromo-2-ethyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the chloro-2-ethyl of-4'--5-fluorine phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (16):
Mp 261-263℃；EIMS m/z:646[M +]；IR(KBr)cm ﹣1:1682(C＝O)，3580(NH)； 1H NMR(DMSO-d 6)δppm：8.05(t，1H)，7.73(m，2H)，7.48-7.55(m，3H)，6.91(s，2H)，6.16(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.85(m，6H)，2.1(m，1H)，1.84(s，3H)，1.25(m，6H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxy-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the chloro-5-of-4'-fluoro-2-methoxyl group phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (17):
Mp 257-259℃；EIMS m/z:570[M +]；IR(KBr)cm ﹣1:1680(C＝O)，3584(NH)； 1H NMR(DMSO-d 6)δppm：8.06(t，1H)，7.82(s，1H)7.79(m，2H)，7.46-7.54(m，3H)，6.91(s，2H)，6.17(d，1H)，5.28(m，1H)，4.79(m，1H)，4.54(m，1H)，4.02(m，1H)，3.89(s，3H)，3.03-3.68(m，16H)，2.53-2.88(m，,2H)，2.47(s，3H)，2.4(m，1H)，1.88(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-4'-chloro-2-ethoxy-5-fluorine phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (18):
Mp 251-253℃；EIMS m/z:539[M +]；IR(KBr)cm ﹣1:1681(C＝O)，3582(NH)； 1H NMR(DMSO-d 6)δppm：8.58(s，1H)，8.33(s，1H)，8.06(t，1H)，7.71(m，2H)，7.47-7.53(m，3H)，6.93(s，2H)，6.12(d，1H)，5.28(m，1H)，4.78(m，1H)，4.56(m，1H)，4.01-4.04(m，3H)，3.03-3.68(m，16H)，2.52-2.86(m，,2H)，2.4(m，1H)，1.87(s，3H)，1.32(t，3H)。
N-(((S)-3-(2-amino-6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-bromo-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-4'-chloro-5-fluorine phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (19):
Mp 259-261℃；EIMS m/z:610[M +]；IR(KBr)cm ﹣1:1680(C＝O)，3580(NH)； 1H NMR(DMSO-d 6)δppm：8.07(t，1H)，7.71(m，2H)，7.42-7.58(m，3H)，6.98(s，2H)，6.21(s，2H)，6.14(d，1H)，5.26(m，1H)，4.72(m，1H)，4.57(m，1H)，4.03(m，1H)，3.08-3.68(m，16H)，2.51-2.85(m，,2H)，2.47(s，3H)，2.1(m，1H)，1.85(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-of the chloro-5-of-4'-(methylamino-) phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (20):
Mp 248-250℃；EIMS m/z:538[M +]；IR(KBr)cm ﹣1:1678(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.58(s，1H)，8.35(s，1H)，8.03(t，1H)，7.73(m，2H)，7.48-7.55(m，3H)，6.93(s，2H)，6.16(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.0-4.06(m，2H)，3.08-3.62(m，19H)，2.56-2.81(m，2H)，2.0(m，1H)，1.84(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-fluoro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-4'-bromo-5-fluorine phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (21):
Mp 253-255℃；EIMS m/z:550[M +]；IR(KBr)cm ﹣1:1679(C＝O)，3583(NH)； 1H NMR(DMSO-d 6)δppm：8.15(s，1H)，8.06(t，1H)，7.61(m，3H)，7.57(m，3H)，6.93(s，2H)，6.14(d，1H)，5.27(m，1H)，4.73(m，1H)，4.57(m，1H)，4.03(m，1H)，3.08-3.64(m，16H)，2.56-2.85(m，2H)，2.2(m，1H)，1.83(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(the bromo-2-methyl of 6-amino-8--9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base) bromo-2, the 5-difluorodiphenyl base-3-bases of-4'-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (22):
Mp 261-263℃；EIMS m/z:604[M +]；IR(KBr)cm ﹣1:1675(C＝O)，3587(NH)； 1H NMR(DMSO-d 6)δppm：8.03(t，1H)，7.30-7.51(m，5H)，6.92(s，2H)，6.12(d，1H)，5.25(m，1H)，4.77(m，1H)，4.53(m，1H)，4.0-4.05(m，1H)，3.08-3.67(m，16H)，2.53-2.86(m，2H)，2.42(s，3H)，2.0(m，1H)，1.82(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-bromo-2-ethyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the bromo-2-of-4'-chloro-5-fluorine phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (23):
Mp 253-255℃；EIMS m/z:584[M +]；IR(KBr)cm ﹣1:1678(C＝O)，3582(NH)； 1H NMR(DMSO-d 6)δppm：8.07(t，1H)，7.61(m，2H)，7.47-7.56(m，3H)，6.97(s，2H)，6.13(d，1H)，5.23(m，1H)，4.78(m，1H)，4.54(m，1H)，4.02(m，1H)，3.08-3.61(m，16H)，2.54-2.81(m，4H)，2.1(m，1H)，1.87(s，3H)，1.22(t，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxy-2-methyl-9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-2,4'-bis-bromo-5-fluorine phenylbenzene-3-bases)-2-oxygen is for oxazolidine-5-base) methyl) ethanamide (24):
Mp 259-261℃；EIMS m/z:630[M +]；IR(KBr)cm ﹣1:1677(C＝O)，3581(NH)； 1H NMR(DMSO-d 6)δppm：8.05(t，1H)，7.86(s，1H)，7.61(m，2H)，7.42-7.51(m，3H)，6.93(s，2H)，6.13(d，1H)，5.26(m，1H)，4.71(m，1H)，4.56(m，1H)，4.02(m，1H)，3.03-3.66(m，16H)，2.52-2.84(m，2H)，2.41(s，3H)，2.0(m，1H)，1.86(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-fluoro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-nitrophenyl of the bromo-5-of-4'--3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (25):
Mp 254-256℃；EIMS m/z:586[M +]；IR(KBr)cm ﹣1:1679(C＝O)，3581(NH)； 1H NMR(DMSO-d 6)δppm：8.16(s，1H)，8.02(t，1H)，7.73(m，1H)，7.61(m，2H)，7.56(m，2H)，6.92(s，2H)，6.18(d，1H)，5.26(m，1H)，4.72(m，1H)，4.58(m，1H)，4.05(m，1H)，3.08-3.64(m，16H)，2.57-2.81(m，2H)，2.1(m，1H)，1.88(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-bromo-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the bromo-2-cyano group of-4'--5-fluorine phenylbenzene-3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (26):
Mp 251-252℃；EIMS m/z:555[M +]；IR(KBr)cm ﹣1:1677(C＝O)，3584(NH)； 1H NMR(DMSO-d 6)δppm：8.04(t，1H)，7.66-7.71(m，3H)，7.57(m，2H)，6.93(s，2H)，6.18(d，1H)，5.24(m，1H)，4.72(m，1H)，4.53(m，1H)，4.09(m，1H)，3.07-3.63(m，16H)，2.52-2.84(m，2H)，2.42(s，3H)，2.3(m，1H)，1.83(s，3H)。
3-((S)-5-(acetamidomethyl)-2-Yang Dai oxazolidine-3-base)-6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-4'-bromo-5-fluorine phenylbenzene-2-carboxylic acid (27):
Mp 265-267℃；EIMS m/z:626[M +]；IR(KBr)cm ﹣1:1679(C＝O)，3583(NH)； 1H NMR(DMSO-d 6)δppm：11(s，1H)，8.11(s，1H)，8.07(t，1H)，7.51-7.84(m，6H)，6.93(s，2H)，6.15(d，1H)，5.27(m，1H)，4.73(m，1H)，4.52(m，1H)，4.04(m，1H)，3.09-3.61(m，16H)，2.58-2.81(m，2H)，2.1(m，1H)，1.89(s，3H)。
N-(((S)-3-(6-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-bromo-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-hydroxy diphenyl of the bromo-5-of-4'--3-base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (28):
Mp 250-251℃；EIMS m/z:554[M +]；IR(KBr)cm ﹣1:1679(C＝O)，3582(NH)； 1H NMR(DMSO-d 6)δppm：8.07(t，1H)，7.62(m，2H)，7.31-7.55(m，3H)，6.94(s，2H)，6.13(d，1H)，5.36(s，1H)，5.21(m，1H)，4.74(m，1H)，4.55(m，1H)，4.03(m，1H)，3.08-3.65(m，16H)，2.52-2.87(m，2H)，2.42(s，3H)，2.0(m，1H)，1.86(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(the fluoro-9H-purine of 6-amino-8--9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base) fluoro-2, the 3-3,5-dimethylphenyls of-5-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (29):
Mp 252-254℃；EIMS m/z:566[M +]；IR(KBr)cm ﹣1:1677(C＝O)，3580(NH)； 1H NMR(DMSO-d 6)δppm：8.16(s，1H)，8.01(t，1H)，7.24(m，1H)，6.92(s，2H)，6.12(d，1H)，5.26(m，1H)，4.72(m，1H)，4.58(m，1H)，4.02(m，1H)，3.08-3.66(m，16H)，2.53-2.85(m，2H)，2.13(s，6H)，2.2(m，1H)，1.87(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-chloro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-3-aminomethyl phenyl of-2-ethyl-5-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (30):
Mp 265-267℃；EIMS m/z:620[M +]；IR(KBr)cm ﹣1:1679(C＝O)，3582(NH)； 1H NMR(DMSO-d 6)δppm：8.12(s，1H)，8.07(t，1H)，7.32(m，1H)，6.91(s，2H)，6.15(d，1H)，5.24(m，1H)，4.73(m，1H)，4.57(m，1H)，4.04(m，1H)，3.03-3.66(m，16H)，2.53-2.89(m，4H)，2.17(s，3H)，2.0(m，1H)，1.82(s，3H)，1.25(t，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-methoxyl group of-5--3-aminomethyl phenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (31):
Mp 262-264℃；EIMS m/z:600[M +]；IR(KBr)cm ﹣1:1676(C＝O)，3586(NH)； 1H NMR(DMSO-d 6)δppm：8.53(s，1H)，8.31(s，1H)，8.05(t，1H)，7.23(m，1H)，6.94(s，2H)，6.12(d，1H)，5.26(m，1H)，4.71(m，1H)，4.55(m，1H)，4.02(m，1H)，3.87(s，3H)，3.08-3.64(m，16H)，2.52-2.87(m，2H)，2.31(s，3H)，2.1(m，1H)，1.85(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-oxyethyl group of-5--3-aminomethyl phenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (32):
Mp 269-271℃；EIMS m/z:646[M +]；IR(KBr)cm ﹣1:1675(C＝O)，3587(NH)； 1H NMR(DMSO-d 6)δppm：8.58(s，1H)，8.35(s，1H)，8.01(t，1H)，7.28(m，1H)，6.93(s，2H)，6.11(d，1H)，5.26(m，1H)，4.73(m，1H)，4.52(m，1H)，4.01-4.09(m，3H)，3.08-3.68(m，16H)，2.53-2.85(m，2H)，2.31(s，3H)，2.0(m，1H)，1.81(s，3H),1.32(t，3H)。
N-(((S)-3-(2-amino-4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-3-aminomethyl phenyl of-5-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (33):
Mp 267-269℃；EIMS m/z:630[M +]；IR(KBr)cm ﹣1:1679(C＝O)，3582(NH)； 1H NMR(DMSO-d 6)δppm：8.51(s，1H)，8.38(s，1H)，8.02(t，1H)，7.11(m，1H)，6.93(s，2H)，6.22(s，2H)，6.19(d，1H)，5.28(m，1H)，4.72(m，1H)，4.58(m，1H)，4.02(m，1H)，3.08-3.64(m，16H)，2.51-2.84(m，2H)，2.32(s，3H)，2.2(m，1H)，1.87(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-3-methyl of-5--2-(methylamino-) phenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (34):
Mp 257-259℃；EIMS m/z:599[M +]；IR(KBr)cm ﹣1:1678(C＝O)，3580(NH)； 1H NMR(DMSO-d 6)δppm：8.38(s，1H)，8.02(t，1H)，7.15(m，1H)，6.97(s，2H)，6.24(s，2H)，6.16(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.0-4.06(m，2H)，3.04-3.62(m，19H)，2.56-2.85(m，2H)，2.44(s，3H)，2.0(m，1H)，1.84(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(the bromo-2-methyl of 6-amino-8--9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-3-ethyl-5-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (35):
Mp 277-279℃；EIMS m/z:670[M +]；IR(KBr)cm ﹣1:1683(C＝O)，3585(NH)； 1H NMR(DMSO-d 6)δppm：8.05(t，1H)，7.32-7.39(m，2H)，6.95(s，2H)，6.12(d，1H)，5.27(m，1H)，4.74(m，1H)，4.56(m，1H)，4.04(m，1H)，3.08-3.67(m，16H)，2.51-2.85(m，4H)，2.43(s，3H)，2.1(m，1H)，1.87(s，3H),1.29(t，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxy-2-methyl-9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-3-ethyl-2,5-difluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (36):
Mp 258-260℃；EIMS m/z:598[M +]；IR(KBr)cm ﹣1:1681(C＝O)，3582(NH)； 1H NMR(DMSO-d 6)δppm：8.07(t，1H)，7.85(s，1H)，7.32(m，1H)，6.93(s，2H)，6.15(d，1H)，5.28(m，1H)，4.72(m，1H)，4.56(m，1H)，4.03(m，1H)，3.08-3.61(m，16H)，2.52-2.84(m，4H)，2.42(s，3H)，2.0(m，1H)，1.84(s，3H),1.25(t，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-bromo-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the chloro-3-ethyl of-2--5-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (37):
Mp 262-264℃；EIMS m/z:610[M +]；IR(KBr)cm ﹣1:1678(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.12(s，1H)，8.05(t，1H)，7.32(m，1H)，6.96(s，2H)，6.12(d，1H)，5.24(m，1H)，4.73(m，1H)，4.55(m，1H)，4.03(m，1H)，3.04-3.61(m，16H)，2.52-2.87(m，4H)，2.1(m，1H)，1.83(s，3H),1.22(t，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-3-p-methoxy-phenyl of the bromo-5-of-2-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (38):
Mp 269-271℃；EIMS m/z:664[M +]；IR(KBr)cm ﹣1:1679(C＝O)，3583(NH)； 1H NMR(DMSO-d 6)δppm：8.52(s，1H)，8.34(s，1H)，8.06(t，1H)，6.99-7.01(m，3H)，6.12(d，1H)，5.26(m，1H)，4.72(m，1H)，4.56(m，1H)，4.04(m，1H)，3.81(s，3H)，3.08-3.67(m，16H)，2.52-2.81(m，2H)，2.2(m，1H)，1.88(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-chloro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-3-methoxyl group of-5--2-nitrophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (39):
Mp 267-269℃；EIMS m/z:644[M +]；IR(KBr)cm ﹣1:1682(C＝O)，3580(NH)； 1H NMR(DMSO-d 6)δppm：8.11(s，1H)，8.01(t，1H)，7.33(m，1H)，6.92(m，2H)，6.17(d，1H)，5.29(m，1H)，4.71(m，1H)，4.51(m，1H)，4.06(m，1H)，3.83(s，3H)，3.08-3.62(m，16H)，2.56-2.81(m，2H)，2.0(m，1H)，1.84(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxy-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-3-p-methoxy-phenyl of-2-cyano group-5-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (40):
Mp 269-271℃；EIMS m/z:690[M +]；IR(KBr)cm ﹣1:1681(C＝O)，3580(NH)； 1H NMR(DMSO-d 6)δppm：8.01(t，1H)，7.86(s，1H)，7.32(m，1H)，6.99(m，2H)，6.13(d，1H)，5.24(m，1H)，4.72(m，1H)，4.56(m，1H)，4.02(m，1H)，3.81(s，3H)，3.08-3.65(m，16H)，2.51-2.85(m，2H)，2.41(s，3H)，2.1(m，1H)，1.87(s，3H)。
6-((S)-5-(acetamidomethyl)-2-Yang Dai oxazolidine-3-base)-3-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-O-Anisic Acid of-4-(41):
Mp 247-249℃；EIMS m/z:570[M +]；IR(KBr)cm ﹣1:1679(C＝O)，3577(NH)； 1H NMR(DMSO-d 6)δppm：11(s，1H)，8.32(s，1H)，8.06(t，1H)，7.32(m，1H)，6.93(m，2H)，6.11(d，1H)，5.26(m，1H)，4.73(m，1H)，4.58(m，1H)，4.02(m，1H)，3.84(s，3H)，3.03-3.68(m，16H)，2.54-2.88(m，2H)，2.43(s，3H)，2.3(m，1H)，1.82(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-chloro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-5-fluoro-2-hydroxy 3-methoxybenzene base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (42):
Mp 242-244℃；EIMS m/z:539[M +]；IR(KBr)cm ﹣1:1677(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.11(s，1H)，8.06(t，1H)，6.91-6.93(m，3H)，6.12(d，1H)，5.35(s，1H)，5.22(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06(m，1H)，3.83(s，3H)，3.08-3.62(m，16H)，2.56-2.81(m，2H)，2.0(m，1H)，1.84(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-3-oxyethyl group-5-fluoro-2-methylbenzene base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (43):
Mp 253-255℃；EIMS m/z:610[M +]；IR(KBr)cm ﹣1:1682(C＝O)，3576(NH)； 1H NMR(DMSO-d 6)δppm：8.18(s，1H)，8.02(t，1H)，7.81(s，1H)，6.97-7.01(m，3H)，6.13(d，1H)，5.25(m，1H)，4.73(m，1H)，4.59(m，1H)，4.03-4.06(m，3H)，3.04-3.62(m，16H)，2.53-2.86(m，2H)，2.32(s，3H)，2.2(m，1H)，1.86(s，3H)，1.32(t，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-3-oxyethyl group-2-ethyl-5-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (44):
Mp 242-243℃；EIMS m/z:538[M +]；IR(KBr)cm ﹣1:1685(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.58(s，1H)，8.31(s，1H)，8.05(t，1H)，6.92-7.08(m，3H)，6.19(d，1H)，5.23(m，1H)，4.72(m，1H)，4.56(m，1H)，4.03-4.08(m，3H)，3.04-3.65(m，16H)，2.53-2.85(m，4H)，2.0(m，1H)，1.86(s，3H)，1.23-1.37(m，6H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-fluoro-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-p-methoxy-phenyl of-3-oxyethyl group-5-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (45):
Mp 245-247℃；EIMS m/z:550[M +]；IR(KBr)cm ﹣1:1681(C＝O)，3576(NH)； 1H NMR(DMSO-d 6)δppm：8.05(t，1H)，6.91-7.04(m，3H)，6.13(d，1H)，5.26(m，1H)，4.73(m，1H)，4.56(m，1H)，4.02-4.09(m，3H)，3.81(s，3H)，3.04-3.62(m，16H)，2.55-2.87(m，2H)，2.42(s，3H)，2.2(m，1H)，1.84(s，3H)，1.32(t，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxyl-9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-2,3-diethoxy-5-fluorophenyls)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (46):
Mp 256-258℃；EIMS m/z:604[M +]；IR(KBr)cm ﹣1:1684(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.11(s，1H)，8.02(t，1H)，7.82(s，1H)，6.99-7.02(m，3H)，6.16(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06-4.09(m，5H)，3.08-3.65(m，16H)，2.56-2.81(m，2H)，2.0(m，1H)，1.83(s，3H)，1.36(t，6H)。
N-(((S)-3-(2-amino-4-(4-(2-(((2R; 3S; 4R; 5R)-5-(the bromo-2-methyl of 6-amino-8--9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-3-oxyethyl group-5-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (47):
Mp 252-254℃；EIMS m/z:584[M +]；IR(KBr)cm ﹣1:1682(C＝O)，3577(NH)； 1H NMR(DMSO-d 6)δppm：8.03(t，1H)，6.92(s，2H)，6.86(m，1H)，6.23(s，2H)，6.12(d，1H)，5.24(m，1H)，4.72(m，1H)，4.58(m，1H)，4.02-4.07(m，3H)，3.04-3.65(m，16H)，2.53-2.86(m，2H)，2.42(s，3H)，2.1(m，1H)，1.88(s，3H)，1.31(t，3H)。
N-(((S)-3-(3-amino-4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-of-5-(methylamino-) phenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (48):
Mp 258-260℃；EIMS m/z:630[M +]；IR(KBr)cm ﹣1:1683(C＝O)，3578(NH)； 1H NMR(DMSO-d 6)δppm：8.53(s，1H)，8.32(s，1H)，8.09(t，1H)，6.99(s，2H)，6.74(m，1H)，6.21(s，2H)，6.17(d，1H)，5.28(m，1H)，4.72(m，1H)，4.57(m，1H)，4.01-4.04(m，2H)，3.02-3.66(m，19H)，2.52-2.85(m，2H)，2.0(m，1H)，1.84(s，3H)。
N-(((S)-3-(3-amino-4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-5-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (49):
Mp 251-253℃；EIMS m/z:586[M +]；IR(KBr)cm ﹣1:1684(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.11(s，1H)，8.03(t，1H)，7.82(s，1H)，6.93-6.97(m，3H)，6.54(m，1H)，6.27(s，2H)，6.16(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.03(m，1H)，3.08-3.61(m，16H)，2.56-2.85(m，2H)，2.1(m，1H)，1.87(s，3H)。
N-(((S)-3-(3-amino-4-(4-(2-(((2R; 3S; 4R; 5R)-5-(the bromo-2-methyl of 6-amino-8--9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-2,5-difluorophenyls)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (50):
Mp 247-249℃；EIMS m/z:555[M +]；IR(KBr)cm ﹣1:1681(C＝O)，3576(NH)； 1H NMR(DMSO-d 6)δppm：8.07(t，1H)，6.92-6.98(m，3H)，6.23(s，2H)，6.15(d，1H)，5.28(m，1H)，4.73(m，1H)，4.56(m，1H)，4.03(m，1H)，3.08-3.68(m，16H)，2.53-2.87(m，2H)，2.41(s，3H)，2.3(m，1H)，1.85(s，3H)。
N-(((S)-3-(3-amino-4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-chloro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the chloro-5-fluorophenyl of-2-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (51):
Mp 257-259℃；EIMS m/z:626[M +]；IR(KBr)cm ﹣1:1685(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.18(s，1H)，8.02(t，1H)，6.92(s，2H)，6.81(m，1H)，6.24(s，2H)，6.12(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.81(m，2H)，2.0(m，1H)，1.84(s，3H)。
N-(((S)-3-(3-amino-4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-2-ethyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the bromo-5-fluorophenyl of-2-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (52):
Mp 242-244℃；EIMS m/z:554[M +]；IR(KBr)cm ﹣1:1681(C＝O)，3588(NH)； 1H NMR(DMSO-d 6)δppm：8.32(s，1H)，8.01(t，1H)，6.93(s，2H)，6.82(m，1H)，6.27(s，2H)，6.16(d，1H)，5.27(m，1H)，4.72(m，1H)，4.56(m，1H)，4.02(m，1H)，3.04-3.61(m，16H)，2.54-2.85(m，4H)，2.1(m，1H)，1.86(s，3H)，1.25(t，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-3-of-5-(methylamino-)-2-nitrophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (53):
Mp 245-247℃；EIMS m/z:566[M +]；IR(KBr)cm ﹣1:1684(C＝O)，3585(NH)； 1H NMR(DMSO-d 6)δppm：8.51(s，1H)，8.33(s，1H)，8.03(t，1H)，7.15(m，1H)，6.99(s，2H)，6.12(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.0-4.06(m，2H)，3.08-3.62(m，19H)，2.56-2.89(m，2H)，2.0(m，1H)，1.84(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-fluoro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-3-of-2-cyano group-5-(methylamino-) phenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (54):
Mp 257-259℃；EIMS m/z:620[M +]；IR(KBr)cm ﹣1:1680(C＝O)，3581(NH)； 1H NMR(DMSO-d 6)δppm：8.11(s，1H)，8.06(t，1H)，6.91-7.07(m，3H)，6.15(d，1H)，5.25(m，1H)，4.73(m，1H)，4.53(m，1H)，4.0-4.05(m，2H)，3.03-3.66(m，19H)，2.52-2.87(m，2H)，2.2(m，1H)，1.89(s，3H)。
6-((S)-5-(acetamidomethyl)-2-Yang Dai oxazolidine-3-base)-3-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-fluoro-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-of-4-(methylamino-) phenylformic acid (55):
Mp 252-254℃；EIMS m/z:600[M +]；IR(KBr)cm ﹣1:1683(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：11(s，1H)，8.03(t，1H)，7.10(m，1H)，6.93(m，2H)，6.19(d，1H)，5.23(m，1H)，4.75(m，1H)，4.51(m，1H)，4.0-4.03(m，2H)，3.02-3.66(m，19H)，2.53-2.84(m，2H)，2.41(s，3H)，2.0(m，1H)，1.82(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-hydroxyl of-5--3-(methylamino-) phenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (56):
Mp 262-264℃；EIMS m/z:646[M +]；IR(KBr)cm ﹣1:1682(C＝O)，3578(NH)； 1H NMR(DMSO-d 6)δppm：8.13(s，1H)，8.07(t，1H)，7.81(s，1H)，6.93(m，2H)，6.72(m，1H)，6.15(d，1H)，5.08(s，1H)，5.23(m，1H)，4.77(m，1H)，4.53(m，1H)，4.0-4.02(m，2H)，3.02-3.64(m，19H)，2.58-2.83(m，2H)，2.2(m，1H)，1.86(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(the bromo-2-methyl of 6-amino-8--9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-5-fluoro-2-methylbenzene base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (57):
Mp 266-268℃；EIMS m/z:630[M +]；IR(KBr)cm ﹣1:1681(C＝O)，3574(NH)； 1H NMR(DMSO-d 6)δppm：8.02(t，1H)，7.47(m，1H)，6.96(m，2H)，6.66(m，1H)，6.14(d，1H)，5.23(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.81(m，2H)，2.44(s，3H)，2.12(s，3H)，2.0(m，1H)，1.85(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-3-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (58):
Mp 260-262℃；EIMS m/z:599[M +]；IR(KBr)cm ﹣1:1686(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.54(s，1H)，8.37(s，1H)，8.05(t，1H)，7.59(m，1H)，6.92(m，2H)，6.81(m，1H)，6.74(m，1H)，6.18(d，1H)，5.22(m，1H)，4.76(m，1H)，4.58(m，1H)，4.01(m，1H)，3.06-3.68(m，16H)，2.53-2.88(m，2H)，2.2(m，1H)，1.82(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-fluoro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-p-methoxy-phenyl of-5-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (59):
Mp 269-272℃；EIMS m/z:670[M +]；IR(KBr)cm ﹣1:1682(C＝O)，3575(NH)； 1H NMR(DMSO-d 6)δppm：8.16(s，1H)，8.03(t，1H)，7.46(m，1H)，6.99(m，2H)，6.27(m，1H)，6.16(d，1H)，5.24(m，1H)，4.77(m，1H)，4.51(m，1H)，4.06(m，1H)，3.83(s，3H)，3.06-3.62(m，16H)，2.56-2.81(m，2H)，2.0(m，1H)，1.84(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-2-oxyethyl group-5-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (60):
Mp 258-260℃；EIMS m/z:598[M +]；IR(KBr)cm ﹣1:1684(C＝O)，3578(NH)； 1H NMR(DMSO-d 6)δppm：8.56(s，1H)，8.35(s，1H)，8.07(t，1H)，7.42(m，1H)，6.93(m，2H)，6.25(m，1H)，6.12(d，1H)，5.21(m，1H)，4.75(m，1H)，4.56(m，1H)，4.03-4.06(m，3H)，3.08-3.67(m，16H)，2.53-2.87(m，2H)，2.7(m，1H)，1.81(s，3H)，1.32(t，3H)。
N-(((S)-3-(2-amino-4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-chloro-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-5-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (61):
Mp 259-261℃；EIMS m/z:610[M +]；IR(KBr)cm ﹣1:1686(C＝O)，3575(NH)； 1H NMR(DMSO-d 6)δppm：8.05(t，1H)，7.31(m，1H)，6.93(m，2H)，6.29(m，2H)，6.13(d，1H)，5.82(m，1H)，5.24(m，1H)，4.72(m，1H)，4.58(m，1H)，4.04(m，1H)，3.01-3.62(m，16H)，2.53-2.85(m，2H)，2.41(s，3H)，2.3(m，1H)，1.88(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-bromo-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-of-5-(methylamino-) phenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (62):
Mp 273-275℃；EIMS m/z:664[M +]；IR(KBr)cm ﹣1:1680(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.13(s，1H)，8.06(t，1H)，7.32(m，1H)，6.95(m，2H)，6.19(d，1H)，5.86(m，1H)，5.27(m，1H)，4.72(m，1H)，4.56(m，1H)，4.0-4.02(m，2H)，3.04-3.67(m，19H)，2.53-2.87(m，2H)，2.1(m，1H)，1.84(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-3,5-difluorophenyls)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (63):
Mp 265-267℃；EIMS m/z:644[M +]；IR(KBr)cm ﹣1:1682(C＝O)，3578(NH)； 1H NMR(DMSO-d 6)δppm：8.58(s，1H)，8.35(s，1H)，8.03(t，1H)，7.34(m，2H)，6.99(m，2H)，6.16(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.81(m，2H)，2.0(m，1H)，1.86(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(the fluoro-9H-purine of 6-amino-8--9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-2; 3,5-trifluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (64):
Mp 269-271℃；EIMS m/z:690[M +]；IR(KBr)cm ﹣1:1681(C＝O)，3576(NH)； 1H NMR(DMSO-d 6)δppm：8.16(s，1H)，8.07(t，1H)，7.35(m，1H)，6.96(m，2H)，6.13(d，1H)，5.28(m，1H)，4.72(m，1H)，4.57(m，1H)，4.03(m，1H)，3.02-3.66(m，16H)，2.53-2.86(m，2H)，2.2(m，1H)，1.84(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxyl-9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base) chloro-3, the 5-difluorophenyls of-2-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (65):
Mp 254-256℃；EIMS m/z:567[M +]；IR(KBr)cm ﹣1:1680(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.14(s，1H)，8.03(t，1H)，7.82(s，1H)，7.28(m，1H)，6.95(m，2H)，6.16(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.81(m，2H)，2.0(m，1H)，1.87(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(the bromo-2-methyl of 6-amino-8--9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base) bromo-3, the 5-difluorophenyls of-2-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (66):
Mp 246-248℃；EIMS m/z:536[M +]；IR(KBr)cm ﹣1:1683(C＝O)，3576(NH)； 1H NMR(DMSO-d 6)δppm：8.05(t，1H)，7.23(m，1H)，6.94(m，2H)，6.11(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.52-2.85(m，2H)，2.44(s，3H)，2.1(m，1H)，1.84(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(the bromo-2-ethyl of 6-amino-8--9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-3,5-bis-fluoro-2-nitrophenyls)-2-oxygen is for oxazolidine-5-base) methyl) ethanamide (67):
Mp 261-263℃；EIMS m/z:607[M +]；IR(KBr)cm ﹣1:1678(C＝O)，3584(NH)； 1H NMR(DMSO-d 6)δppm：8.06(t，1H)，7.61(m，1H)，6.93(m，2H)，6.12(d，1H)，5.27(m，1H)，4.72(m，1H)，4.57(m，1H)，4.03(m，1H)，3.01-3.64(m，16H)，2.53-2.86(m，4H)，2.0(m，1H)，1.82(s，3H)，1.25(t，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the chloro-2-cyano group of-3--5-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (68):
Mp 246-248℃；EIMS m/z:535[M +]；IR(KBr)cm ﹣1:1681(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.49(s，2H)，8.26(s，1H)，8.05(t，1H)，7.50(s，1H)，7.12(m，2H)，5.21(m，1H)，4.51(m，2H)，4.2(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.85(m，2H)，2.1(m，1H)，1.84(s，3H)。
6-((S)-5-(acetamidomethyl)-2-Yang Dai oxazolidine-3-base)-3-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-fluoro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the chloro-4-fluorobenzoic acid (69) of-2-:
Mp 251-253℃；EIMS m/z:547[M +]；IR(KBr)cm ﹣1:1675(C＝O)，3580(NH)； 1H NMR(DMSO-d 6)δppm：11(s，1H)，8.15(s，1H)，8.02(t，1H)，7.68(m，1H)，6.94(m，2H)，6.16(d，1H)，5.26(m，1H)，4.71(m，1H)，4.54(m，1H)，4.08(m，1H)，3.01-3.65(m，16H)，2.53-2.88(m，2H)，2.3(m，1H)，1.89(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-bromo-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the chloro-5-fluoro-2-hydroxyphenyl of-3-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (70):
Mp 270-272℃；EIMS m/z:601[M +]；IR(KBr)cm ﹣1:1682(C＝O)，3575(NH)； 1H NMR(DMSO-d 6)δppm：8.16(s，1H)，8.07(t，1H)，7.28(m，1H)，6.99(m，2H)，6.13(d，1H)，5.35(s，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.85(m，2H)，2.0(m，1H)，1.84(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-bromo-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-3-chloro-5-fluoro-2-methylbenzene base)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (71):
Mp 252-254℃；EIMS m/z:581[M +]；IR(KBr)cm ﹣1:1678(C＝O)，3582(NH)； 1H NMR(DMSO-d 6)δppm：8.03(t，1H)，7.33(m，1H)，6.92(m，2H)，6.16(d，1H)，5.26(m，1H)，4.73(m，1H)，4.55(m，1H)，4.07(m，1H)，3.08-3.61(m，16H)，2.52-2.88(m，2H)，2.44(s，3H)，2.21(s，3H)，2.2(m，1H)，1.87(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the chloro-2-ethyl of-3--5-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (72):
Mp 258-260℃；EIMS m/z:627[M +]；IR(KBr)cm ﹣1:1679(C＝O)，3580(NH)； 1H NMR(DMSO-d 6)δppm：8.58(s，1H)，8.35(s，1H)，8.06(t，1H)，7.40(m，1H)，6.94(m，2H)，6.13(d，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.81(m，4H)，2.0(m，1H)，1.84(s，3H)，1.25(t，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-fluoro-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-p-methoxy-phenyl of the chloro-5-of-3-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (73):
Mp 257-259℃；EIMS m/z:597[M +]；IR(KBr)cm ﹣1:1683(C＝O)，3574(NH)； 1H NMR(DMSO-d 6)δppm：8.07(t，1H)，7.32(m，1H)，6.97(m，2H)，6.14(d，1H)，5.28(m，1H)，4.72(m，1H)，4.58(m，1H)，4.02(m，1H)，3.87(s，3H)，3.02-3.67(m，16H)，2.52-2.87(m，2H)，2.42(s，3H)，2.1(m，1H)，1.89(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-chloro-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-3-chloro-2-ethoxy-5-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (74):
Mp 252-254℃；EIMS m/z:566[M +]；IR(KBr)cm ﹣1:1680(C＝O)，3577(NH)； 1H NMR(DMSO-d 6)δppm：8.05(t，1H)，7.32(m，1H)，6.98(m，2H)，6.12(d，1H)，5.26(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06-4.09(m，3H)，3.08-3.62(m，16H)，2.56-2.81(m，2H)，2.44(s，3H)，2.0(m，1H)，1.84(s，3H)，1.32(t，3H)。
N-(((S)-3-(2-amino-4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the chloro-5-fluorophenyl of-3-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (75):
Mp 259-261℃；EIMS m/z:637[M +]；IR(KBr)cm ﹣1:1675(C＝O)，3580(NH)； 1H NMR(DMSO-d 6)δppm：8.15(s，1H)，8.03(t，1H)，7.82(s，1H)，7.20(m，1H)，6.99(m，2H)，6.27(s，2H)，6.16(d，1H)，5.21(m，1H)，4.72(m，1H)，4.58(m，1H)，4.05(m，1H)，3.04-3.64(m，16H)，2.53-2.85(m，2H)，2.1(m，1H)，1.87(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-of the chloro-5-of-3-(methylamino-) phenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (76):
Mp 252-254℃；EIMS m/z:565[M +]；IR(KBr)cm ﹣1:1680(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.58(s，1H)，8.35(s，1H)，8.05(t，1H)，7.23(m，1H)，6.93(m，2H)，6.13(d，1H)，5.26(m，1H)，4.75(m，1H)，4.51(m，1H)，4.0-4.06(m，2H)，3.08-3.62(m，19H)，2.56-2.81(m，2H)，2.0(m，1H)，1.84(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-bromo-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the bromo-5-fluorophenyl of-3-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (77):
Mp 252-254℃；EIMS m/z:577[M +]；IR(KBr)cm ﹣1:1679(C＝O)，3584(NH)； 1H NMR(DMSO-d 6)δppm：8.16(s，1H)，8.07(t，1H)，7.46-7.51(m，2H)，6.99(m，2H)，6.16(d，1H)，5.21(m，1H)，4.74(m，1H)，4.57(m，1H)，4.02(m，1H)，3.04-3.65(m，16H)，2.52-2.84(m，2H)，2.1(m，1H)，1.87(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base) bromo-2, the 5-difluorophenyls of-3-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (78):
Mp 273-275℃；EIMS m/z:631[M +]；IR(KBr)cm ﹣1:1686(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.58(s，1H)，8.35(s，1H)，8.03(t，1H)，7.49(m，1H)，6.92(m，2H)，6.13(d，1H)，5.27(m，1H)，4.72(m，1H)，4.51(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.81(m，2H)，2.0(m，1H)，1.83(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-fluoro-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the chloro-5-fluorophenyl of the bromo-2-of-3-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (79):
Mp 258-260℃；EIMS m/z:611[M +]；IR(KBr)cm ﹣1:1684(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.07(t，1H)，7.42(m，1H)，6.91(m，2H)，6.12(d，1H)，5.24(m，1H)，4.72(m，1H)，4.59(m，1H)，4.02(m，1H)，3.05-3.61(m，16H)，2.52-2.87(m，2H)，2.42(s，3H)，2.2(m，1H)，1.86(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxy-2-methyl-9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base)-2,3-bis-bromo-5-fluorophenyls)-2-oxygen is for oxazolidine-5-base) methyl) ethanamide (80):
Mp 266-268℃；EIMS m/z:657[M +]；IR(KBr)cm ﹣1:1685(C＝O)，3579(NH)； 1H NMR(DMSO-d 6)δppm：8.02(t，1H)，7.85(s，1H)，7.42(m，1H)，6.96(m，2H)，6.12(d，1H)，5.29(m，1H)，4.75(m，1H)，4.51(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.56-2.81(m，2H)，2.44(s，3H)，2.0(m，1H)，1.82(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2-nitrophenyl of the bromo-5-of-3-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (81):
Mp 252-254℃；EIMS m/z:566[M +]；IR(KBr)cm ﹣1:1684(C＝O)，3575(NH)； 1H NMR(DMSO-d 6)δppm：8.58(s，1H)，8.35(s，1H)，8.01(t，1H)，7.77(m，1H)，6.99(m，2H)，6.16(d，1H)，5.21(m，1H)，4.77(m，1H)，4.51(m，1H)，4.01(m，1H)，3.03-3.61(m，16H)，2.56-2.81(m，2H)，2.2(m，1H)，1.84(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-fluoro-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the bromo-2-cyano group of-3--5-fluorophenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (82):
Mp 251-253℃；EIMS m/z:535[M +]；IR(KBr)cm ﹣1:1682(C＝O)，3578(NH)； 1H NMR(DMSO-d 6)δppm：8.12(s，1H)，8.06(t，1H)，7.69(m，1H)，6.92(m，2H)，6.14(d，1H)，5.27(m，1H)，4.73(m，1H)，4.59(m，1H)，4.06(m，1H)，3.08-3.62(m，16H)，2.51-2.85(m，2H)，2.0(m，1H)，1.89(s，3H)。
6-((S)-5-(acetamidomethyl)-2-Yang Dai oxazolidine-3-base)-3-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-hydroxy-2-methyl-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base) the fluoro-2 hydroxybenzoic acid of-4-(83):
Mp 267-269℃；EIMS m/z:606[M +]；IR(KBr)cm ﹣1:1681(C＝O)，3577(NH)； 1H NMR(DMSO-d 6)δppm：11(s，1H)，8.04(t，1H)，7.82(s，1H)，7.34(m，1H)，6.94(m，2H)，6.16(d，1H)，5.35(s，1H)，5.21(m，1H)，4.75(m，1H)，4.51(m，1H)，4.02(m，1H)，3.01-3.66(m，16H)，2.56-2.81(m，2H)，2.44(s，3H)，2.1(m，1H)，1.82(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-9H-purine-9-base)-3; 4-dihydroxytetrahydrofandn-2-base) methylamino-) ethanoyl) piperazine-1-base) fluoro-2, the 3-dihydroxy phenyls of-5-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (84):
Mp 250-252℃；EIMS m/z:534[M +]；IR(KBr)cm ﹣1:1681(C＝O)，3576(NH)； 1H NMR(DMSO-d 6)δppm：8.58(s，1H)，8.32(s，1H)，8.01(t，1H)，6.92-6.95(m，3H)，6.14(d，1H)，5.32(s，2H)，5.25(m，1H)，4.73(m，1H)，4.58(m，1H)，4.02(m，1H)，3.01-3.68(m，16H)，2.52-2.89(m，2H)，2.0(m，1H)，1.83(s，3H)。
N-(((S)-3-(4-(4-(2-(((2R; 3S; 4R; 5R)-5-(6-amino-8-bromo-9H-purine-9-base)-3,4-dihydroxytetrahydrofandn-2-bases) methylamino-) ethanoyl) piperazine-1-base)-5-fluoro-3-hydroxy-2-methyl phenyl)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide (85):
Mp 261-263℃；EIMS m/z:546[M +]；IR(KBr)cm ﹣1:1683(C＝O)，3583(NH)； 1H NMR(DMSO-d 6)δppm：8.12(s，1H)，8.05(t，1H)，6.92-7.07(m，3H)，6.12(d，1H)，5.38(s，1H)，5.22(m，1H)，4.73(m，1H)，4.57(m，1H)，4.03(m，1H)，3.01-3.62(m，16H)，2.52-2.87(m，2H)，2.31(s，3H)，2.1(m，1H)，1.87(s，3H)。

Claims (4)

1. a class Linezolid-adenosine type Mutiple Targets antimicrobial compounds, they have following general structure:
Formula iin:
R 1=Me, Et, OMe, OEt, NH 2, NHMe, H, F, Cl, Br, NO 2, CN, CO 2h or OH, R 2= , , , , Me, Et, OMe, OEt, NH 2, NHMe, H, F, Cl, Br or OH, R 3=H, F, Cl, Br or OH, R 4=H, Me or Et.
2. prepare a method for above-mentioned Linezolid-adenosine type Mutiple Targets antimicrobial compounds, it comprises the following steps:
Step 1: will ( r)-5-phthalimide methyl-2-oxazolidone ( iII) and salt of wormwood join in toluene, every g iIIuse toluene 5-18mL, after dissolving, room temperature reaction 0.5-6h, and then add 2-R 1-3-R 2the fluoro-4-of-5-(4 '-tert-butoxycarbonyl-piperazine base) bromobenzene ( iI) and cuprous chloride, the ratio of amount of substance: iI: iII: salt of wormwood: cuprous chloride=1:1:(2-7): (0.1-0.9), when solution is muddy gradually, adds compound iIIthe benzyltriethylammoinium chloride of the 5%-10% of consumption, is warming up to back flow reaction 15-24h, reacts complete, boils off toluene, add water, dichloromethane extraction, and organic phase saturated sodium bicarbonate, saturated sodium-chloride wash, anhydrous MgSO 4drying, concentrated, silica gel column chromatography, eluent is sherwood oil-AcOEt, and the volume ratio of sherwood oil and AcOEt is 20:1-8:1, ( r)-( n-(2 '-R 1-3 '-R 2-5 '-fluoro-4 '-(4 ' '-tert-butoxycarbonyl-piperazine base)) phenyl-2-oxo-5-oxazolidinyl) methyl phthalimide ( iV);
Step 2: will ( r)-( n-(2 '-R 1-3 '-R 2-5 '-fluoro-4 '-(4 ' '-tert-butoxycarbonyl-piperazine base)) phenyl-2-oxo-5-oxazolidinyl) methyl phthalimide ( iV) join in methyl alcohol, every g iVuse methyl alcohol 7-30mL, after dissolving, add the hydrazine hydrate that massfraction is 80%, the ratio of amount of substance: iV: anhydrous hydrazine=1:(5-8), be warming up to 50 DEG C, react 3-15h under nitrogen protection, react complete, concentrated, enriched material is water-soluble, and with dichloromethane extraction, saturated sodium-chloride washs, anhydrous MgSO 4drying, concentrated, dissolve enriched material with toluene, add diacetyl oxide, after dropwising, room temperature reaction 2-10h, reacts complete, suction filtration, filter residue methanol wash, ( r)- n-tertiary fourth oxygen formyl radical-4-(4-(5-(ethanamide methyl)-2-Yang Dai oxazolidine-3-base)-2-R 2-3-R 1-6-fluorophenyl) piperazine ( v), by compound ( v) be dissolved in methylene dichloride, every g vuse methylene dichloride 6-20mL, after to be dissolved, add 80% trifluoroacetic acid aqueous solution, the ratio of amount of substance: v: trifluoroacetic acid=1:(2-7), room temperature reaction 4-14h, after reaction terminates, under ice bath with in saturated sodium bicarbonate solution and, dichloromethane extraction 3 times, concentrated, silica gel column chromatography, eluent is sherwood oil-AcOEt, and the volume ratio of sherwood oil and AcOEt is 15:1-3:1, ( r)-4-(4-(5-(ethanamide methyl)-2-Yang Dai oxazolidine-3-base)-2-R 2-3-R 1-6-fluorophenyl) piperazine ( vI);
Step 3: by 2-R 4-8-R 3-2 ', 3 '-isopropylidene adenosine ( vII) and phthalic imidine be dissolved in THF, every g vIIuse THF 6-15mL, after dissolving, instill diisopropyl azodiformate (DIAD), the ratio of amount of substance: vII: PPh 3: phthalic imidine: DIAD=1:(1.5-3): (1.5-5): (2-8), dropwises and react 7-24h under room temperature, reacts complete, concentrated, with the dissolve with ethanol of the anhydrous hydrazine containing 5%-10%, the ratio of amount of substance: vII: anhydrous hydrazine=1:(3-8), backflow 30min, is cooled to room temperature, filters, uses ethanol rinse filter residue, and filtrate concentrates, and silica gel column chromatography, eluent is sherwood oil-AcOEt, and the volume ratio of sherwood oil and AcOEt is 15:1-2:1, obtains white solid 2-R 4-8-R 3-5 '-aminomethyl-2 ', 3 '-isopropylidene adenosine ( vIII);
Step 4: by 2-R 4-8-R 3-5 '-aminomethyl-2 ', 3 '-isopropylidene adenosine ( vIII) join in DMF, every g vIIIuse DMF 8-18mL, after dissolving, add triethylamine and ethyl bromoacetate, the ratio of amount of substance: vIII: triethylamine: ethyl bromoacetate=1:(5-8): (2-3), react 8-22h under nitrogen protection, react complete, add the distilled water of 3 times of DMF volumes, extract 3 times with AcOEt, saturated common salt water washing, anhydrous MgSO 4drying, concentrated, obtain-2-(((3a r, 4 r, 6 r, 6a r)-6-(6-amino-2-R 4-8-R 3-9 h-purine-9-base)-2,2-dimethyl-tetrahydrofurans [3,4-d] [1,3] dioxolane-4-base) methylamino-) ethyl acetate ( iX), by compound ( iX) be dissolved in THF, every g iXuse THF 8-15mL, after to be dissolved, add 10% aqueous sodium hydroxide solution, the ratio of amount of substance: iX: sodium hydroxide=1:(1.5-3), room temperature reaction 5-26h, after reaction terminates, add dilute hydrochloric acid neutralization, extract 3 times with AcOEt, concentrated, silica gel column chromatography, eluent is the sherwood oil-AcOEt of 1% acetic acid, and the volume ratio of sherwood oil and AcOEt is 8:1-1:2, obtains 2-(((3a r, 4 r, 6 r, 6a r)-6-(6-amino-2-R 4-8-R 3-9 h-purine-9-base)-2,2-dimethyl-tetrahydrofurans [3,4-d] [1,3] dioxolane-4-base) methylamino-) acetic acid ( x);
Step 5: by 2-(((3a r, 4 r, 6 r, 6a r)-6-(6-amino-2-R 4-8-R 3-9 h-purine-9-base)-2,2-dimethyl-tetrahydrofurans [3,4-d] [1,3] dioxolane-4-base) methylamino-) acetic acid ( x) and ( r)-4-(4-(5-(ethanamide methyl)-2-Yang Dai oxazolidine-3-base)-2-R 2-3-R 1-6-fluorophenyl) piperazine ( vI) add in methylene dichloride, every g xuse methylene dichloride 5-20mL, add TBTU and triethylamine after to be dissolved, the ratio of amount of substance is: x: iV: TBTU: triethylamine=1:(1.2-2): (1.5-3): (2-8), room temperature backflow 5-17h, after completion of the reaction, concentrated, column chromatography, eluent is the chloroform-methanol containing 0.1% acetic acid, the volume ratio of chloroform and methyl alcohol is 80:1-40:1, n-((( s)-3-(4-(4-(2-(((3a r, 4 r, 6 r, 6a r)-6-(6-amino-2-R 4-8-R 3-9 h-purine-9-base)-2,2-dimethyl-tetrahydrofurans [3,4-d] [1,3] dioxolane-4-base) methylamino-) ethanoyl) piperazine-1-base)-2-R 1-3-R 2the fluoro-phenyl of-5-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide ( xI);
Step 6: will n-((( s)-3-(4-(4-(2-(((3a r, 4 r, 6 r, 6a r)-6-(6-amino-2-R 4-8-R 3-9 h-purine-9-base)-2,2-dimethyl-tetrahydrofurans [3,4-d] [1,3] dioxolane-4-base) methylamino-) ethanoyl) piperazine-1-base)-2-R 1-3-R 2the fluoro-phenyl of-5-)-2-Yang Dai oxazolidine-5-base) methyl) ethanamide ( xI) be dissolved in methylene dichloride, every g xIIuse methylene dichloride 8-30mL, after to be dissolved, add 80% trifluoroacetic acid, the ratio of amount of substance: xII: trifluoroacetic acid=1:(1.5-3), room temperature reaction 7-18h, after, with saturated sodium bicarbonate solution neutralization, extraction into ethyl acetate 3 times, saturated common salt water washing, anhydrous MgSO 4drying, concentrated, silica gel column chromatography, eluent is chloroform-methanol, and the volume ratio of chloroform and methyl alcohol is 60:1-20:1, obtain Linezolid-adenosine type compound ( i);
Wherein said R 1, R 2, R 3and R 4definition identical with above-mentioned definition.
3. the application of a class Linezolid-adenosine type compound according to claim 1 in preparation antibacterials, described compound can act on rrna 50S subunit and tyrosyl-t RNA synthetase simultaneously.
4. a class Linezolid-adenosine type compound according to claim 1 is preparing the application in anti-infectives.
CN201410534207.7A 2014-10-11 2014-10-11 Linezolid-adenosine type multi-target-point antibacterial compound as well as preparation method and application thereof Pending CN104341475A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410534207.7A CN104341475A (en) 2014-10-11 2014-10-11 Linezolid-adenosine type multi-target-point antibacterial compound as well as preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410534207.7A CN104341475A (en) 2014-10-11 2014-10-11 Linezolid-adenosine type multi-target-point antibacterial compound as well as preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN104341475A true CN104341475A (en) 2015-02-11

Family

ID=52497997

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410534207.7A Pending CN104341475A (en) 2014-10-11 2014-10-11 Linezolid-adenosine type multi-target-point antibacterial compound as well as preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN104341475A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266666A1 (en) * 2003-05-23 2004-12-30 Fatheree Paul R. Cross-linked glycopeptide-cephalosporin antibiotics
CN1777577A (en) * 2003-01-08 2006-05-24 希龙公司 Antibacterial agents
CN101765585A (en) * 2007-06-12 2010-06-30 尔察祯有限公司 Antiseptic-germicide
WO2014012014A1 (en) * 2012-07-13 2014-01-16 Massachusetts Institute Of Technology Methods and products related to protozoan disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777577A (en) * 2003-01-08 2006-05-24 希龙公司 Antibacterial agents
US20040266666A1 (en) * 2003-05-23 2004-12-30 Fatheree Paul R. Cross-linked glycopeptide-cephalosporin antibiotics
CN101765585A (en) * 2007-06-12 2010-06-30 尔察祯有限公司 Antiseptic-germicide
WO2014012014A1 (en) * 2012-07-13 2014-01-16 Massachusetts Institute Of Technology Methods and products related to protozoan disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GÁBOR PINTÉR，等: "The Effect of Systematic Structural Modifications on the Antibacterial Activity of Novel Oxazolidinones", 《MEDICINAL CHEMISTRY》 *
JEEWOO LEE，等: "Ester and Hydroxamate Analogues of Methionyl and Isoleucyl Adenylates as Inhibitors of Methionyl-tRNA and Isoleucyl-tRNA Synthetases", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
PAMELA BROWN，等: "Molecular Recognition of Tyrosinyl Adenylate Analogues by Prokaryotic Tyrosyl tRNA Synthetases", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
王庆，等: "氨酰tRNA合成酶抑制剂作为新型抗感染药物的研究进展", 《现代生物医学进展》 *

Similar Documents

Publication Publication Date Title
Abdel-Wahab et al. Design and synthesis of new 4-pyrazolin-3-yl-1, 2, 3-triazoles and 1, 2, 3-triazol-4-yl-pyrazolin-1-ylthiazoles as potential antimicrobial agents
EP3024827B1 (en) Substituted quinazolin-4-one derivatives
Hannoun et al. Synthesis and antibacterial evaluation of a novel library of 2-(thiazol-5-yl)-1, 3, 4-oxadiazole derivatives against methicillin-resistant Staphylococcus aureus (MRSA)
Li et al. Design, synthesis and antibacterial activity of cinnamaldehyde derivatives as inhibitors of the bacterial cell division protein FtsZ
CN104829598B (en) Quinazolinone compound containing 1, 2, 4-triazole thioether and synthesizing method and application of quinazolinone compound
KR101738866B1 (en) Cyclic N,N'-diarylthioureas and N,N'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
CN106188031B (en) Thiazole orange styrene derivative and preparation method thereof and preparing the application in drug-resistance bacteria medicine
CN112724157B (en) Dihydrooxazolo [5,4-d ] pyrrolo [1,2-a ] pyrimidin-9 (5H) -one derivatives and use thereof
CN102119157A (en) Tricyclic 2,4-diamino-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
Szulczyk et al. Design and synthesis of novel 1H-tetrazol-5-amine based potent antimicrobial agents: DNA topoisomerase IV and gyrase affinity evaluation supported by molecular docking studies
Salian et al. Spectroscopic, single crystal X-ray, Hirshfeld, in vitro and in silico biological evaluation of a new series of potent thiazole nucleus integrated with pyrazoline scaffolds
CN113788846B (en) Tricyclic thiazolo [5,4-d ] pyrimidinone derivative and application thereof
CN105712998A (en) Azaindole derivatives, preparation method and applications thereof in medicine
WO2021088787A1 (en) Quinazoline compound used as axl inhibitor
CN107698567A (en) Isatin azoles alcohol compound and preparation method thereof and medical applications
CN103739589A (en) N-(2,3-dihydro benzo [b] thiapyran-4-imino)-N'-(4-methyl phenyl) guanidine derivative and application thereof
Kadi RETRACTED: Synthesis and antimicrobial activity of some new quinazolin-4 (3H)-one derivatives
Chandak et al. Synthesis and biological evaluation of some novel thiazolylhydrazinomethylideneferrocenes as antimicrobial agents
CN101058573B (en) 2-hydrazone substituted triazine compound, preparation method thereof, and medicinal composition and use using same as active component
CN104341475A (en) Linezolid-adenosine type multi-target-point antibacterial compound as well as preparation method and application thereof
J Khairnar et al. Synthesis and Antimicrobial Activity of Some New 1, 4‐Benzothiazine Containing Thiosemicarbazides and 1, 3, 4‐Oxadiazole Derivatives
CN104341476A (en) Linezolid-inosine type multi-target antibacterial compounds as well as preparation method and application thereof
CN105481778A (en) Pyrimidine derivative, preparation method and applications thereof
CN102775371B (en) Substituted thiadiazine derivatives, as well as preparation method and application thereof
CN104327140B (en) Oxazolidone-adenosine type Mutiple Targets antimicrobial compound and method for making thereof and purposes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150211